Publikationen, an denen er mitarbeitet Juan Carlos Prieto Villapún (21)

2016

  1. Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer

    Oncotarget, Vol. 7, Núm. 32, pp. 52195-52206

2014

  1. Growth hormone-releasing hormone antagonists abolish the transactivation of human epidermal growth factor receptors in advanced prostate cancer models

    Investigational New Drugs, Vol. 32, Núm. 5, pp. 871-882

2013

  1. Antitumoral effects of vasoactive intestinal peptide in human renal cell carcinoma xenografts in athymic nude mice

    Cancer Letters, Vol. 336, Núm. 1, pp. 196-203

  2. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer

    International Journal of Cancer, Vol. 132, Núm. 4, pp. 755-765

2012

  1. Overexpression of vasoactive intestinal peptide receptors and cyclooxygenase-2 in human prostate cancer. Analysis of potential prognostic relevance

    Histology and Histopathology, Vol. 27, Núm. 8, pp. 1093-1101

2010

  1. Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer

    Peptides, Vol. 31, Núm. 11, pp. 2035-2045

  2. Vasoactive intestinal peptide (VIP) induces malignant transformation of the human prostate epithelial cell line RWPE-1

    Cancer Letters, Vol. 299, Núm. 1, pp. 11-21

2009

  1. Multifunctional role of VIP in prostate cancer progression in a xenograft model: Suppression by curcumin and COX-2 inhibitor NS-398

    Peptides, Vol. 30, Núm. 12, pp. 2357-2364

2005

  1. Pituitary adenylate cyclase-activating peptide/vasoactive intestinal peptide receptors in human normal mammary gland and breast cancer tissue

    Gynecological Endocrinology, Vol. 20, Núm. 6, pp. 327-333

2004

  1. PACAP expression and distribution in human breast cancer and healthy tissue

    Cancer Letters, Vol. 205, Núm. 2, pp. 189-195

2003

  1. Expression of functional PACAP/VIP receptors in human prostate cancer and healthy tissue

    Peptides, Vol. 24, Núm. 6, pp. 893-902

  2. VIP and PACAP receptors coupled to adenylyl cyclase in human lung cancer: A study in biopsy specimens

    Peptides, Vol. 24, Núm. 3, pp. 429-436

2002

  1. Expression and distribution of pituitary adenylate cyclase-activating peptide in human prostate and prostate cancer tissues

    Regulatory Peptides, Vol. 110, Núm. 1, pp. 9-15

2001

  1. Vasoactive intestinal peptide (VIP) stimulates rat prostatic epithelial cell proliferation

    Prostate, Vol. 47, Núm. 4, pp. 285-292

2000

  1. Immunohistochemical and immunochemical evidence for expression of human lung PACAP/VIP receptors

    Annals of the New York Academy of Sciences

  2. Immunohistochemical localization and distribution of VIP/PACAP receptors in human lung

    Peptides, Vol. 21, Núm. 2, pp. 265-269

1999

  1. Effects of chronic ethanol ingestion on the vasoactive intestinal peptide receptor-effector system from rat seminal vesicle membranes

    Alcoholism: Clinical and Experimental Research, Vol. 23, Núm. 2, pp. 318-323

1998

  1. G-protein regulation of adenylate cyclase activity in rat prostatic membranes after chronic ethanol ingestion

    Prostate, Vol. 36, Núm. 4, pp. 226-234

1997

  1. Identification of a protein-tyrosine phosphatase (SHP1) different from that associated with acid phosphatase in rat prostate

    FEBS Letters, Vol. 406, Núm. 1-2, pp. 42-48

1988

  1. Partial enterectomy decreases somatostatin-binding sites in residual intestine of rabbits

    Clinical Science, Vol. 74, Núm. 5, pp. 499-505